title: The therapeutic effect of OK-432-combined adoptive immunotherapy against liver metastases from breast cancer.
abstract: We studied the therapeutic effect of OK-432 combined with adoptive immunotherapy in 19 cases of liver metastases from breast cancer. Of the 14 patients who received intraarterial OK-432 injection and transfer of cultured lymphocytes, 9 responded to this therapy, whereas no patients responded to intravenous administration. The minimum cell number for a therapeutic response was 8 x 10(8) cells. Metastatic lesions other than those in the liver regressed after therapy in 4 patients. The serum carcinoembryonic antigen level paralleled the therapeutic effect. There were no severe side-effects accompanying this therapy. These results indicate that intraarterial adoptive immunotherapy combined with OK-432 is effective as a new therapeutic approach against liver metastases from breast cancer.
authors.affiliation: First Department of Surgery, Kyoto University, School of Medicine, Japan.
authors.forename: T
authors.initials: T
authors.lastname: Okino
authors.forename: N
authors.initials: N
authors.lastname: Kan
authors.forename: M
authors.initials: M
authors.lastname: Nakanishi
authors.forename: K
authors.initials: K
authors.lastname: Satoh
authors.forename: K
authors.initials: K
authors.lastname: Mise
authors.forename: Y
authors.initials: Y
authors.lastname: Teramura
authors.forename: S
authors.initials: S
authors.lastname: Yamasaki
authors.forename: T
authors.initials: T
authors.lastname: Hori
authors.forename: H
authors.initials: H
authors.lastname: Kodama
authors.forename: K
authors.initials: K
authors.lastname: Ohgaki
mesh_terms: D000328:Adult; D000368:Aged; D001688:Biological Products / Q000627:therapeutic use*; D001943:Breast Neoplasms / Q000628:therapy*; D002272:Carcinoembryonic Antigen / Q000032:analysis; D003602:Cytotoxicity, Immunologic; D005260:Female; D006801:Humans; D007116:Immunization, Passive; D015979:Killer Cells, Lymphokine-Activated / Q000276:immunology; D008113:Liver Neoplasms / Q000000981:diagnostic imaging / Q000556:secondary* / Q000628:therapy; D008214:Lymphocytes / Q000276:immunology*; D008875:Middle Aged; D010844:Picibanil / Q000627:therapeutic use*; D011859:Radiography
chemical_list: D001688:Biological Products; D002272:Carcinoembryonic Antigen; D010844:Picibanil